MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- ASTRAZENECA PHARMA - CIPLA
ASTRAZENECA PHARMA vs CIPLA - Comparison Results
ASTRAZENECA PHARMA Change
AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
CIPLA 
Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More
Current Valuations
| ASTRAZENECA PHARMA | CIPLA | ASTRAZENECA PHARMA/ CIPLA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 106.9 | 33.8 | 316.4% | View Chart |
| P/BV | x | 31.2 | 3.5 | 897.8% | View Chart |
| Dividend Yield | % | 0.0 | 0.5 | - |
Financials
 ASTRAZENECA PHARMA  CIPLA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ASTRAZENECA PHARMA Mar-18 |
CIPLA Mar-19 |
ASTRAZENECA PHARMA/ CIPLA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,278 | 678 | 188.5% | |
| Low | Rs | 883 | 484 | 182.4% | |
| Sales per share (Unadj.) | Rs | 228.4 | 198.2 | 115.2% | |
| Earnings per share (Unadj.) | Rs | 10.4 | 18.5 | 56.0% | |
| Cash flow per share (Unadj.) | Rs | 16.3 | 35.0 | 46.5% | |
| Dividends per share (Unadj.) | Rs | 0 | 3.00 | 0.0% | |
| Dividend yield (eoy) | % | 0 | 0.5 | 0.0% | |
| Book value per share (Unadj.) | Rs | 98.8 | 186.3 | 53.0% | |
| Shares outstanding (eoy) | m | 25.00 | 805.70 | 3.1% | |
| Bonus/Rights/Conversions | - | ESOP | - | ||
| Price / Sales ratio | x | 4.7 | 2.9 | 161.4% | |
| Avg P/E ratio | x | 104.2 | 31.4 | 332.4% | |
| P/CF ratio (eoy) | x | 66.4 | 16.6 | 400.1% | |
| Price / Book Value ratio | x | 10.9 | 3.1 | 350.8% | |
| Dividend payout | % | 0 | 16.2 | 0.0% | |
| Avg Mkt Cap | Rs m | 27,008 | 468,031 | 5.8% | |
| No. of employees | `000 | 1.4 | 22.6 | 6.0% | |
| Total wages/salary | Rs m | 1,535 | 28,565 | 5.4% | |
| Avg. sales/employee | Rs Th | 4,210.9 | 7,053.1 | 59.7% | |
| Avg. wages/employee | Rs Th | 1,132.2 | 1,261.5 | 89.8% | |
| Avg. net profit/employee | Rs Th | 191.1 | 659.1 | 29.0% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 5,710 | 159,710 | 3.6% | |
| Other income | Rs m | 123 | 4,766 | 2.6% | |
| Total revenues | Rs m | 5,833 | 164,475 | 3.5% | |
| Gross profit | Rs m | 463 | 30,973 | 1.5% | |
| Depreciation | Rs m | 147 | 13,263 | 1.1% | |
| Interest | Rs m | 0 | 1,684 | 0.0% | |
| Profit before tax | Rs m | 438 | 20,791 | 2.1% | |
| Minority Interest | Rs m | 0 | -172 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 179 | 5,695 | 3.1% | |
| Profit after tax | Rs m | 259 | 14,924 | 1.7% | |
| Gross profit margin | % | 8.1 | 19.4 | 41.8% | |
| Effective tax rate | % | 40.8 | 27.4 | 149.1% | |
| Net profit margin | % | 4.5 | 9.3 | 48.6% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 3,209 | 124,266 | 2.6% | |
| Current liabilities | Rs m | 2,070 | 37,715 | 5.5% | |
| Net working cap to sales | % | 20.0 | 54.2 | 36.8% | |
| Current ratio | x | 1.6 | 3.3 | 47.1% | |
| Inventory Days | Days | 72 | 91 | 79.8% | |
| Debtors Days | Days | 35 | 95 | 36.8% | |
| Net fixed assets | Rs m | 790 | 105,190 | 0.8% | |
| Share capital | Rs m | 50 | 1,611 | 3.1% | |
| "Free" reserves | Rs m | 2,419 | 148,511 | 1.6% | |
| Net worth | Rs m | 2,469 | 150,123 | 1.6% | |
| Long term debt | Rs m | 0 | 38,301 | 0.0% | |
| Total assets | Rs m | 4,605 | 239,633 | 1.9% | |
| Interest coverage | x | NM | 13.3 | - | |
| Debt to equity ratio | x | 0 | 0.3 | 0.0% | |
| Sales to assets ratio | x | 1.2 | 0.7 | 186.0% | |
| Return on assets | % | 5.6 | 6.9 | 81.2% | |
| Return on equity | % | 10.5 | 9.9 | 105.5% | |
| Return on capital | % | 17.7 | 11.8 | 149.8% | |
| Exports to sales | % | 0 | 34.7 | 0.0% | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | 55,419 | 0.0% | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 300 | 57,410 | 0.5% | |
| Fx outflow | Rs m | 2,015 | 19,041 | 10.6% | |
| Net fx | Rs m | -1,715 | 38,368 | -4.5% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 88 | 16,911 | 0.5% | |
| From Investments | Rs m | -94 | -16,687 | 0.6% | |
| From Financial Activity | Rs m | NA | -3,487 | 0.0% | |
| Net Cashflow | Rs m | -6 | -3,451 | 0.2% | |
Share Holding
| Indian Promoters | % | 0.0 | 16.0 | - | |
| Foreign collaborators | % | 75.0 | 20.8 | 360.6% | |
| Indian inst/Mut Fund | % | 0.3 | 12.2 | 2.5% | |
| FIIs | % | 15.7 | 23.7 | 66.2% | |
| ADR/GDR | % | 0.0 | 1.1 | - | |
| Free float | % | 9.1 | 26.2 | 34.7% | |
| Shareholders | 12,856 | 161,166 | 8.0% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASTRAZENECA PHARMA With: ALEMBIC PHARMA STRIDES PHARMA SCIENCE TTK HEALTHCARE JUBILANT LIFE SCIENCES BIOCON
Compare ASTRAZENECA PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Today's Market
Sensex Opens Over 750 Points Higher; Banking Stocks Rally(09:30 am)
Asian stock markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 1.4% while the Hang Seng is up 3.1%.
Related Views on News
CIPLA at 52 Week High; BSE 500 Index Up 2.0% (Market Updates)
Jun 1, 2020 | Updated on Jun 1, 2020CIPLA share price has hit a 52-week high. It is presently trading at Rs 652. BSE 500 Index is up by 1.9% at 12,650. Within the BSE 500, CIPLA (up 0.4%) and IDBI BANK (up 18.0%) are among the top gainers, while top losers are VODAFONE IDEA and LA OPALA RG.
ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)
May 20, 2020 | Updated on May 20, 2020For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)
May 19, 2020 | Updated on May 19, 2020For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.
CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)
Feb 6, 2020 | Updated on Feb 6, 2020For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.
CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)
Nov 14, 2019 | Updated on Nov 14, 2019For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.
More Views on NewsMost Popular
6 Charts Showing the State of Indian Financial Markets in 2020(Sector Info)
May 26, 2020Six charts showing how Indian financial markets have performed in 2020 so far...
This 'Essential Product' Smallcap is a Must Have for a 'Covid-19' Immune Portfolio(Profit Hunter)
May 19, 2020This smallcap company needs no stimulus measures to do well in the long term.
What the RBI's Rate Cut Means for Options Traders(Fast Profits Daily)
May 25, 2020The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.
Which Stocks Should You Buy, Sell, and Hold in the Market Today?(Profit Hunter)
May 21, 2020The coronavirus led uncertainty refuses to go away from the markets. Here's what retail investors should do with their stocks...
MoreOUR TOP 5 IDEAS
- How to Trade the Coronavirus Crash - Download this FREE Report Now
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
ASTRAZENECA PHARMA SHARE PRICE
Jun 1, 2020 09:39 AM
TRACK ASTRAZENECA PHARMA
- Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ASTRAZENECA PHARMA
ASTRAZENECA PHARMA 5-YR ANALYSIS
COMPARE ASTRAZENECA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.